• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

雌激素耗竭会改变体外成骨细胞的成骨分化和基质产生。

Estrogen depletion alters osteogenic differentiation and matrix production by osteoblasts in vitro.

机构信息

Mechanobiology and Medical Device Research Group (MMDRG), Biomechanics Research Centre (BMEC), Biomedical Engineering, College of Engineering and Informatics, National University of Ireland Galway, Galway, Ireland.

Mechanobiology and Medical Device Research Group (MMDRG), Biomechanics Research Centre (BMEC), Biomedical Engineering, College of Engineering and Informatics, National University of Ireland Galway, Galway, Ireland; Lehigh University, Bethlehem, PA, USA.

出版信息

Exp Cell Res. 2021 Nov 1;408(1):112814. doi: 10.1016/j.yexcr.2021.112814. Epub 2021 Sep 4.

DOI:10.1016/j.yexcr.2021.112814
PMID:34492267
Abstract

Recent studies have revealed that the effects of estrogen deficiency are not restricted to osteoclasts and bone resorption, but that bone matrix composition is altered and osteoblasts exhibit an impaired response to mechanical stimulation. In this study, we test the hypothesis that estrogen depletion alters osteogenic differentiation and matrix production by mechanically stimulated osteoblasts in vitro. MC3T3-E1 cells were pre-treated with estrogen for 14 days, after which estrogen was withdrawn or inhibited with Fulvestrant up to 14 days. Fluid shear stress (FSS) was applied using an orbital shaker. Under estrogen depletion in static culture, osteogenic marker (ALP) and gene expression (Runx2) were decreased at 2 and after 7 days of estrogen depletion, respectively. In addition, up to 7 day the inhibition of the estrogen receptor significantly decreased fibronectin expression (FN1) under static conditions. Under estrogen depletion and daily mechanical stimulation, changes in expression of Runx2 occurred earlier (4 days) and by 14 days, changes in matrix production (Col1a1) were reported. We propose that changes in osteoblast differentiation and impaired matrix production during estrogen depletion may contribute to the altered quality of the bone and act as a contributing factor to increased bone fragility in postmenopausal osteoporosis.

摘要

最近的研究表明,雌激素缺乏的影响不仅局限于破骨细胞和骨吸收,还会改变骨基质组成,使成骨细胞对机械刺激的反应受损。在这项研究中,我们通过体外实验验证了雌激素耗竭是否会改变机械刺激成骨细胞的成骨分化和基质产生的假设。MC3T3-E1 细胞先用雌激素预处理 14 天,然后用氟维司群(fulvestrant)去除或抑制雌激素,持续 14 天。采用轨道摇床施加流体切应力(FSS)。在静态培养中雌激素耗竭时,成骨标志物(ALP)和基因表达(Runx2)分别在雌激素耗竭 2 天和 7 天后降低。此外,在静态条件下,雌激素受体的抑制作用可显著降低纤连蛋白表达(FN1),持续至 7 天。在雌激素耗竭和每日机械刺激下,Runx2 的表达变化更早(4 天),而在 14 天时,基质产生(Col1a1)的变化也被报道。我们提出,雌激素耗竭期间成骨细胞分化的变化和基质产生受损可能导致骨质量改变,并成为绝经后骨质疏松症骨脆性增加的一个促成因素。

相似文献

1
Estrogen depletion alters osteogenic differentiation and matrix production by osteoblasts in vitro.雌激素耗竭会改变体外成骨细胞的成骨分化和基质产生。
Exp Cell Res. 2021 Nov 1;408(1):112814. doi: 10.1016/j.yexcr.2021.112814. Epub 2021 Sep 4.
2
Cellular and molecular effects of growth hormone and estrogen on human bone cells.生长激素和雌激素对人骨细胞的细胞及分子效应。
APMIS Suppl. 1997;71:1-30.
3
Inhibition of osteoclastogenesis by mechanically stimulated osteoblasts is attenuated during estrogen deficiency.机械刺激的成骨细胞对破骨细胞生成的抑制作用在雌激素缺乏时减弱。
Am J Physiol Cell Physiol. 2019 Nov 1;317(5):C969-C982. doi: 10.1152/ajpcell.00168.2019. Epub 2019 Aug 14.
4
Piezoelectric Microvibration Mitigates Estrogen Loss-Induced Osteoporosis and Promotes Piezo1, MicroRNA-29a, and Wnt3a Signaling in Osteoblasts.压电微振动减轻雌激素缺乏引起的骨质疏松症,并促进成骨细胞中的 Piezo1、miR-29a 和 Wnt3a 信号。
Int J Mol Sci. 2021 Aug 31;22(17):9476. doi: 10.3390/ijms22179476.
5
Involvement of receptor-interacting protein 140 in estrogen-mediated osteoclasts differentiation, apoptosis, and bone resorption.受体相互作用蛋白140参与雌激素介导的破骨细胞分化、凋亡及骨吸收过程。
J Physiol Sci. 2017 Jan;67(1):141-150. doi: 10.1007/s12576-016-0447-2. Epub 2016 Mar 26.
6
Interaction between bone and immune cells: Implications for postmenopausal osteoporosis.骨骼与免疫细胞之间的相互作用:对绝经后骨质疏松症的影响。
Semin Cell Dev Biol. 2022 Mar;123:14-21. doi: 10.1016/j.semcdb.2021.05.014. Epub 2021 May 20.
7
Osteoblastogenesis and osteoprotection enhanced by flavonolignan silibinin in osteoblasts and osteoclasts.水飞蓟宾黄酮醇苷在成骨细胞和破骨细胞中增强成骨生成和护骨作用。
J Cell Biochem. 2012 Jan;113(1):247-59. doi: 10.1002/jcb.23351.
8
Increased Osteoblastic Cxcl9 Contributes to the Uncoupled Bone Formation and Resorption in Postmenopausal Osteoporosis.成骨细胞 Cxcl9 增加导致绝经后骨质疏松症中骨形成和骨吸收解偶联。
Clin Interv Aging. 2020 Jul 20;15:1201-1212. doi: 10.2147/CIA.S254885. eCollection 2020.
9
Estrogen and testosterone use different cellular pathways to inhibit osteoclastogenesis and bone resorption.雌激素和睾酮通过不同的细胞途径抑制破骨细胞生成和骨吸收。
J Bone Miner Res. 2005 Dec;20(12):2224-32. doi: 10.1359/JBMR.050803. Epub 2005 Aug 1.
10
Psoralidin, a prenylated coumestan, as a novel anti-osteoporosis candidate to enhance bone formation of osteoblasts and decrease bone resorption of osteoclasts.补骨脂定,一种异戊烯基化香豆雌酚,作为一种新型抗骨质疏松候选药物,可促进成骨细胞的骨形成并减少破骨细胞的骨吸收。
Eur J Pharmacol. 2017 Apr 15;801:62-71. doi: 10.1016/j.ejphar.2017.03.001. Epub 2017 Mar 8.

引用本文的文献

1
Role and mechanism of botanical drugs and their metabolites in osteoporosis: new strategies for clinical application.植物药及其代谢产物在骨质疏松症中的作用与机制:临床应用新策略
Front Pharmacol. 2025 Aug 12;16:1530194. doi: 10.3389/fphar.2025.1530194. eCollection 2025.
2
Beyond Bone Loss: A Biology Perspective on Osteoporosis Pathogenesis, Multi-Omics Approaches, and Interconnected Mechanisms.超越骨质流失:骨质疏松症发病机制、多组学方法及相互关联机制的生物学视角
Biomedicines. 2025 Jun 12;13(6):1443. doi: 10.3390/biomedicines13061443.
3
A-485 alleviates postmenopausal osteoporosis by activating GLUD1 deacetylation through the SENP1-Sirt3 signal pathway.
A-485通过SENP1-Sirt3信号通路激活GLUD1去乙酰化来缓解绝经后骨质疏松症。
J Orthop Surg Res. 2025 May 29;20(1):542. doi: 10.1186/s13018-025-05839-4.
4
Exploring associations between estrogen and gene candidates identified by coronary artery disease genome-wide association studies.探索雌激素与冠状动脉疾病全基因组关联研究确定的候选基因之间的关联。
Front Cardiovasc Med. 2025 Mar 20;12:1502985. doi: 10.3389/fcvm.2025.1502985. eCollection 2025.
5
Crispant analysis in zebrafish as a tool for rapid functional screening of disease-causing genes for bone fragility.斑马鱼中的crispant分析作为一种快速功能性筛选导致骨脆性疾病基因的工具。
Elife. 2025 Jan 16;13:RP100060. doi: 10.7554/eLife.100060.
6
Pyroptosis mediates osteoporosis via the inflammation immune microenvironment.焦亡通过炎症免疫微环境介导骨质疏松症。
Front Immunol. 2024 Jun 3;15:1371463. doi: 10.3389/fimmu.2024.1371463. eCollection 2024.
7
Mechanistic advances in osteoporosis and anti-osteoporosis therapies.骨质疏松症及抗骨质疏松症治疗的机制进展
MedComm (2020). 2023 May 11;4(3):e244. doi: 10.1002/mco2.244. eCollection 2023 Jun.
8
Estrogen Receptor 1 (ESR1) and the Wnt/β-Catenin Pathway Mediate the Effect of the Coumarin Derivative Umbelliferon on Bone Mineralization.雌激素受体 1(ESR1)和 Wnt/β-连环蛋白通路介导香豆素衍生物 Umbelliferon 对骨矿化的作用。
Nutrients. 2022 Aug 5;14(15):3209. doi: 10.3390/nu14153209.
9
Microgravity-Related Changes in Bone Density and Treatment Options: A Systematic Review.微重力相关的骨密度变化及治疗选择:系统综述。
Int J Mol Sci. 2022 Aug 3;23(15):8650. doi: 10.3390/ijms23158650.
10
Advances in Our Understanding of the Mechanism of Action of Drugs (including Traditional Chinese Medicines) for the Intervention and Treatment of Osteoporosis.我们对药物(包括中药)干预和治疗骨质疏松症作用机制的认识进展
Front Pharmacol. 2022 Jun 14;13:938447. doi: 10.3389/fphar.2022.938447. eCollection 2022.